AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know

AbbVie (ABBV) shares rose 0.17% to $187.66 in the most recent trading session, outperforming the S&P 500 despite a 0.4% decrease over the last month. The company's upcoming EPS is projected to increase by 22.26% year-over-year to $3.24, with revenue expected to grow 3.56% to $14.98 billion; full-year estimates suggest a 21.34% increase in earnings per share and a 6.58% increase in revenue. AbbVie currently holds a Zacks Rank of #3 (Hold) and trades at a forward P/E of 15.25, a premium compared to its industry's average of 13.69.

Analysis

AbbVie (ABBV) demonstrated resilience in its most recent trading session, closing at $187.66 with a 0.17% gain, thereby outperforming the S&P 500's daily loss of 0.53%. Over the past month, the drugmaker's shares have decreased by 0.4%, which, while underperforming the S&P 500's 5.17% gain, notably surpassed the Medical sector's 2.31% loss. Significant attention is now on AbbVie's upcoming earnings report, where the company is projected to deliver an EPS of $3.24, marking a substantial 22.26% increase year-over-year, and revenue of $14.98 billion, a 3.56% growth from the prior year's quarter. For the full year, Zacks Consensus Estimates project earnings of $12.28 per share and revenue of $60.04 billion, reflecting year-over-year increases of 21.34% and 6.58%, respectively. Despite these strong growth projections, the Zacks Consensus EPS estimate has seen a marginal downward revision of 0.02% over the last month, and AbbVie currently holds a Zacks Rank of #3 (Hold). In terms of valuation, AbbVie trades at a Forward P/E ratio of 15.25, a premium compared to its industry's average of 13.69. However, its PEG ratio of 1.24 is aligned with the Large Cap Pharmaceuticals industry average, indicating that its valuation relative to expected growth is comparable to peers. The Large Cap Pharmaceuticals industry itself maintains a strong Zacks Industry Rank of 30, placing it in the top 13% of all industries.

Key Decisions for Investors

• Investors should closely monitor AbbVie's upcoming earnings release to ascertain if the reported figures align with the strong projected EPS growth of 22.26% and revenue growth of 3.56%, as this will be pivotal given the slight recent downward revision in consensus EPS estimates and the current Zacks #3 (Hold) rating.
• Evaluate AbbVie's forward P/E of 15.25, which indicates a premium to its industry, in conjunction with its PEG ratio of 1.24 (in line with the industry average) and robust full-year growth forecasts, to determine if the current valuation adequately reflects its growth prospects and fits within risk tolerance.
• Consider the recent 0.02% downward revision in Zacks Consensus EPS estimate and the stock's relative performance – outperforming its sector but lagging the S&P 500 over the past month – when making decisions, as estimate changes are highlighted as being directly correlated with near-term stock price movements.